Trials / Completed

CompletedNCT00002026

Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)

Status: Completed
Phase: N/A
Study type: Interventional
Enrollment: —

Sponsor: Glaxo Wellcome · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and compare to existing historical control data.

Conditions

Leukoplakia, Hairy
HIV Infections

Interventions

Type	Name	Description
DRUG	Acyclovir

Timeline

First posted: 2001-08-31
Last updated: 2005-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00002026. Inclusion in this directory is not an endorsement.